<DOC>
	<DOCNO>NCT02888080</DOCNO>
	<brief_summary>The purpose study ass ACZ885 improve lung function association reduction tissue inflammation patient chronic sarcoidosis .</brief_summary>
	<brief_title>Study Efficacy , Safety Tolerability ACZ885 ( Canakinumab ) Patients With Pulmonary Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Male female subject age 18 80 year age ( inclusive ) Pulmonary sarcoidosis disease duration ≥1 year Evidence biopsyproven , clinically active disease define follow criterion : 1 . MMRC dyspnea scale ≥1 2 . Threshold FVC 50 80 % predict 3 . Evidence parenchymal lung involvement HRCT Key Treated pulmonary hypertension Previous exposure concomitant treatment within accord follow criterion : 1 . Prednisone &gt; 15 mg/day change prednisone dose 8 week prior screen 2 . More one immunemodulator ( i.e. , methotrexate , azathioprine , leflunomide , hydroxychloroquine ) change dose level within 12 week randomization . 3 . Mycophenolate use within 12 week randomization Prior treatment biologic drug target immune system within 180 day randomization history previous use rituximab History bleeding disorder Forced vital capacity ( FVC ) &lt; 50 % predict Extrapulmonary sarcoidosis primary treatment indication ( e.g. , involve brain , heart , eye renal disease significant hypercalcemia ) Any condition significant medical problem opinion investigator immunecompromise patient and/or place patient unacceptable risk immunomodulatory therapy , : 1 . Absolute neutrophil count ( ANC ) &lt; LLN ( 1,500/μl ) 2 . Thrombocytopenia CTCAE v4.03 Grade 1 : Platelets &lt; LLN ( 75.0 x 109/L ) 3 . Any active recurrent bacterial , fungal ( exception onychomycosis ) viral infection 4 . Presence human immunodeficiency virus ( HIV ) infection , hepatitis B hepatitis C infection base screen lab result 5 . Presence active latent tuberculosis ( TB ) establish screen 6 . Clinical evidence history multiple sclerosis demyelinating disease , Felty 's syndrome Live vaccination within 3 month prior start trial Current severe progressive uncontrolled disease judgment clinical investigator render patient unsuitable trial Women childbearing potential , defined woman physiologically capable become pregnant , unless use method contraception define protocol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pulmonary sarcoidosis</keyword>
	<keyword>sarcoidosis</keyword>
	<keyword>canakinumab</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>granuloma</keyword>
	<keyword>inflammation</keyword>
	<keyword>lung function test</keyword>
	<keyword>immunosuppressive agent</keyword>
	<keyword>interleukin</keyword>
	<keyword>interleukin-1Beta</keyword>
	<keyword>[ F-18 ] FDG-PET/CT</keyword>
	<keyword>respiratory</keyword>
	<keyword>pulmonary</keyword>
	<keyword>steroid</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>lung disease</keyword>
</DOC>